Study of intracellular signaling pathways in Chronic Myeloproliferative Neoplasms
A gain-of-function mutation in Janus kinase 2 (JAK2V617F) is at the basis of the majority of chronic myeloproliferative neoplasms (MPN). Enhanced activation of other downstream pathways including the PI3K/mTOR pathway has been documented as well. In this study we evaluated the effects of JAK1/2 inhi...
Saved in:
| Main Author: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Florence
Firenze University Press
2017
|
| Series: | Premio Tesi di Dottorato
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_83462 | ||
| 005 | 20220602 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20220602s2017 xx |||||o ||| 0|eng d | ||
| 020 | |a 978-88-6453-565-4 | ||
| 020 | |a 9788864535654 | ||
| 020 | |a 9788864535647 | ||
| 020 | |a 9788892731684 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.36253/978-88-6453-565-4 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a MF |2 bicssc | |
| 072 | 7 | |a MQP |2 bicssc | |
| 072 | 7 | |a PS |2 bicssc | |
| 072 | 7 | |a PSB |2 bicssc | |
| 072 | 7 | |a PSD |2 bicssc | |
| 100 | 1 | |a Martinelli, Serena |4 auth | |
| 245 | 1 | 0 | |a Study of intracellular signaling pathways in Chronic Myeloproliferative Neoplasms |
| 260 | |a Florence |b Firenze University Press |c 2017 | ||
| 300 | |a 1 electronic resource (80 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Premio Tesi di Dottorato | |
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a A gain-of-function mutation in Janus kinase 2 (JAK2V617F) is at the basis of the majority of chronic myeloproliferative neoplasms (MPN). Enhanced activation of other downstream pathways including the PI3K/mTOR pathway has been documented as well. In this study we evaluated the effects of JAK1/2 inhibitors, alone and in combination with mTOR, with a dual mTOR/PI3K inhibitor and with a pan PI3K inhibitor in in-vitro and in-vivo MPN models. Our findings of strong synergy between the JAK2 inhibitors and mTOR/PI3K inhibitor suggested that we might be able to administer these drugs at lower concentrations than when the drugs are used individually. This provides a framework for combination trials using compounds in patients with myeloproliferative neoplasms | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Pre-clinical medicine: basic sciences |2 bicssc | |
| 650 | 7 | |a Pharmacy / dispensing |2 bicssc | |
| 650 | 7 | |a Biology, life sciences |2 bicssc | |
| 650 | 7 | |a Biochemistry |2 bicssc | |
| 650 | 7 | |a Molecular biology |2 bicssc | |
| 856 | 4 | 0 | |a www.oapen.org |u https://library.oapen.org/bitstream/20.500.12657/55390/1/9788864535654.pdf |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/83462 |7 0 |z DOAB: description of the publication |